Clinical trials: Blood Plasma Therapy
Cancer-related Problem/Condition, Depression
Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue
A sample of 60 patients scheduled for HSCT in the treatment of MM will be recruited in the weeks to months prior to their hospitalization.
- Conditions
- Cancer-related Problem/Condition, Depression, Circadian Rhythm Disorders
- Trial name
- PEI (NCT03198754)
- Testing
- PEI Experimental Light, Comparison Light
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Multiple Myeloma
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
The purpose of this study is to compare how well Ramantamig plus Daratumumab (ramantamig-D) works compared with a treatment that includes Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd), followed by high-dose…
- Trial name
- TRIlogy-6 (NCT07903272)
- Testing
- Ramantamig, Daratumumab, Bortezomib
- Volunteers
- 1,000 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma
This multicenter, prospective, randomized trial was designed to evaluate the role of thalidomide with or without dexamethasone as a maintenance therapy for multiple myeloma patients after a single autologous stem cell…
- Trial name
- NCT01296503
- Testing
- Thalidomide plus dexamethasone, Dexamethasone
- Where
- 4 sites in Brazil
- Volunteers
- 213 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Multiple Myeloma
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
This will be a multi-center, open label, expanded treatment protocol of panobinostat, bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT02204553
- Testing
- Panobinostat
- Where
- 27 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma
Allogeneic stem cell transplantation (Allo-SCT) in multiple myeloma (MM) remains a controversial topic because of a high risk of relapse and a significant transplant-related mortality (TRM).
- Trial name
- REVALLO (NCT01421927)
- Testing
- Lenalidomide
- Where
- France
- Volunteers
- 13 people
- Sponsor
- University Hospital, Bordeaux
Refractory Multiple Myeloma
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy.
- Trial name
- NCT02020941
- Testing
- carfilzomib, dexamethasone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Attaya Suvannasankha
HSV Infection, HIV Infection
Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons
The purpose of this study is to determine whether treating HSV-2 with either valacyclovir or acyclovir is more effective in suppressing HIV-1 virus levels in people co-infected with HIV-1 and HSV-2.
- Trial name
- ACV-VAL (NCT01026454)
- Testing
- acyclovir, valacyclovir
- Where
- Kenya
- Volunteers
- 32 people
- Sponsor
- University of Washington
Septic Shock
Therapeutic Plasma Exchange in Septic Shock: A Pilot Study
The investigators propose to conduct a multi-center randomized pilot feasibility trial comparing therapeutic plasma exchange to standard of care in patients diagnosed with septic shock.
- Trial name
- PLEXSIS (NCT05093075)
- Testing
- Therapeutic Plasma Exchange
- Where
- 11 sites in Canada
- Volunteers
- 80 people
- Sponsor
- University of Manitoba
Multiple Myeloma
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-BCMA/FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture.
- Trial name
- NCT06759181
- Testing
- anti-BCMA/FcRL5 CAR T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuzhou Medical University
Organophosphorus Poisoning
Fresh Frozen Plasma Transfusion in Acute Organophosphate Poisoning
this study clinical trial to assess the role of fresh frozen plasma as a novel available and easy to be applied rather than conventional therapy on organophosphate poisoned patients and prediction of it is prognosis on selected…
- Trial name
- NCT06256796
- Testing
- fresh frozen plasma
- Where
- Egypt
- Volunteers
- 92 people
- Sponsor
- Ain Shams University
COVID-19
Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program
This is an expanded access treatment protocol to treat up to 100 patients with severe or life-threatening, laboratory confirmed COVID-19 with COVID-19 convalescent plasma.
- Trial name
- NCT04363034
- Testing
- Convalescent Plasma
- Sponsor
- University of Arkansas
Relapse Multiple Myeloma, Refractory Multiple Myeloma
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or…
- Trial name
- NCT07221032
- Testing
- FT836 CAR T cells (1 x 10^8 cells per dose), FT836 CAR T cells (3 x 108 cells per dose), FT836 CAR T cells (up to 9 x 108 cells per dose)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical College of Wisconsin
Multiple Myeloma, Myeloma
FT576 in Subjects With Multiple Myeloma
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
- Trial name
- NCT05182073
- Testing
- FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fate Therapeutics
Myeloma
Machine Learning in Myeloma Response
Diffusion-weighted Whole Body Magnetic Resonance Imaging (WB-MRI) is a new technique that builds on existing Magnetic Resonance Imaging (MRI) technology.
- Trial name
- MALIMAR (NCT03574454)
- Testing
- Machine Learning (ML)
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Osteoarthritis, Knee
Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction
This is a prospective, randomized, placebo-controlled trial to evaluate potential beneficial effects of leukocyte-poor platelet rich plasma and bone marrow concentrate on the healing and health of critical joint tissues in the…
- Trial name
- NCT04205656
- Testing
- Leukocyte-Poor Platelet Rich Plasma (LP-PRP), Bone Marrow Concentrate (BMC)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Steadman Philippon Research Institute
Knee Osteoarthritis
Comparing Effect of Autologous Platelet-Rich Plasma Versus Hyaluronic Acid Treatment on Knee Osteoarthritis
To compare the efficacy and structural change of intraarticular single platelet-rich plasma(PRP) versus novel crosslinked Hyaluronic Acid(HA)(HyajointPlus) for the treatment of early stage knee osteoarthritis(OA).
- Trial name
- NCT04972383
- Testing
- Platelet Rich Plasma, Hyaluronic Acid
- Where
- Taiwan
- Volunteers
- 116 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Acute Lymphoblastic Leukemia, Lymphoma
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT05618041
- Testing
- CAR-T Autologous T cell injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Multiple Myeloma, Relapse Multiple Myeloma
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Patients with relapsed/refractory symptomatic multiple myeloma who meet all inclusion criteria, will be randomized 1:1 to receive either standard of care chemotherapy (IKEMA or ICARIA) and dexamethasone until disease progression…
- Trial name
- FREEDOM (NCT06561854)
- Testing
- Dexamethasone
- Where
- France
- Volunteers
- 318 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
SIL as Maintenance Therapy in Multiple Myeloma
The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.
- Trial name
- NCT06744894
- Testing
- Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy
- Volunteers
- 50 people
- Sponsor
- Navy General Hospital, Beijing
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.